Analysis of virological efficacy in trials of antiretroviral regimens: Drawbacks of not including viral load measurements after premature discontinuation of therapy

Antiviral Therapy

Volumn 7, Issue 4, 2002, Pages 271-281

  Kirk, Ole ^a   Pedersen, Court ^b   Law, Matthew ^c   Gulick, Roy M ^d   Moyle, Graeme ^e   Montaner, Julio ^f   Eron Jr , Joseph J ^g   Phillips, Andrew N ^h   Lundgren, Jens D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEDLINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0036972260     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. Journal of the American Medical Association 2000; 283:381-390.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio MA, Yust I, Bruun JN, Phillips AN & Lundgren JD. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
3. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
4. BHIVA Writing committee. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral treatment. BHIVA Guidelines Co-ordinating Committee. HIV Medicine 2001; 2:276-313.
5. Guidance for Industry. Clinical Considerations for Accelerated and Traditional Approval of Antiretroviral Drugs Using Plasma HIV RNA Measurements. Draft Guidance. Food and Drug Administration/Center for Drug Evaluation and Research, http://www.fda.gov/cder/guidance/3182dft.htm.
6. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M & Lange JM. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Journal of the American Medical Association 1998; 279:930-937.
7. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA & Richman DD. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. Journal of the American Medical Association 1998; 280:35-41.
8. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R & Kuritzkes DR. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. Journal of Infectious Diseases 1999; 179:808-816.
9. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine 1999; 341:1865-1873.
10. Moyle G, Pozniak A, Opravil M, Clumeck N, Delfraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M & Duff F. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe. Journal of Acquired Immune Deficiency Syndrome 2000; 23:128-137.
11. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS 2000; 14:367-374.
12. Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R & Stevens M. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000; 14:1601-1610.
13. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R & Stevens M. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14:1591-1600.
14. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC Jr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A & Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-F9.
15. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H & Spreen W. Abacavir-lamivudine-zidovudine vs indinavirlamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. Journal of the American Medical Association 2001; 285:1155-1163.
16. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP & Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association 2000; 283:229-234.
17. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV & Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. Journal of Virology 1998; 72:2422-2428.
18. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
19. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E & Shivaprakash M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-571.
20. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG & Allan JD. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Annals of Internal Medicine 1990; 112:727-737.
21. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJJ, Feinberg JE, Balfour HHJ, Deyton LR, Chodakewitz JA & Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 1997; 337:725-733.
22. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C & Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. New England Journal of Medicine 1996; 334:1011-1017.
23. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC & Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 2001; 134:663-694.
24. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343:871-881.
25. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 1996; 348:283-291.
26. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP & Hirsch MS. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. New England Journal of Medicine 1995; 333:401-407.
27. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS & Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team [see comments]. New England Journal of Medicine 1996; 335:1081-1090.
28. Pocock SJ. Clinical Trials: A Practical Approach 1983. Chichester: John Wiley.
29. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J & Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and esign. British Journal of Cancer 1976; 34:585-612.
30. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C & Lundgren JD. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999; 13:F9-16.
31. Katzenstein TL, Kirk O, Pedersen C, Lundgren JD, Nielsen H, Obel N, Nielsen C, Mathiesen LR & Gerstoft J. The Danish Protease Inhibitor Study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 Infection. Journal of Infectious Diseases 2000; 182:744-750.
32. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S & Cooper DA. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000; 14:1171-1180.
33. Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, Reiss P, Gatell J, Clumeck N, Dietrich M, Benfield TL, Nielsen JO & Pedersen C. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 16:153-160.
34. Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee. Lancet 1999; 353:2061-2064.
35. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337:734-739.
36. Floridia M, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Weimer LE, Tomino C, Giannini G, Galluzzo CM, Andreotti M, Cargnel A, Alberici F, De Rienzo B, Leoncini F, Fiaccadori F, Francisci D, Grillone W, Ortona L, Piazza M, Scalzini A, Nigra E, Tumietto F & Vella S. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1999; 20:11-19.
37. Kirk O, Gerstoft J, Pedersen C, Nielsen H, Obel N, Katzenstein T, Mathiesen L & Lundgren J. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen. HIV Medicine 2001; 2:43-51.
38. D'Arminio MA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U & Moroni M. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of antiretroviral-naive patients. AIDS 2000; 14:499-507.
39. Chene G, Morlat P, Leport C, Hafner R, Dequae L, Charreau I, Aboulker JP, Luft B, Aubertin J, Vilde JL & Salamon R. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Controlled Clinical Trials 1998; 19:233-248.
40. Juni P, Altman DG & Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. British Medical Journal 2001; 323:42-46.
41. Smeaton LM, DeGruttola V, Robbins GK & Shafer RW. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Controlled Clinical Trials 2001; 22:142-159.
42. An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. Controlled Clinical Trials 2001; 22:160-175.
43. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD & Neaton JD. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Controlled Clinical Trials 2002; 23:198-220.
44. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD & Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13:2075-2082.
45. Gilbert PB, DeGruttola V, Hammer SM & Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. Journal of the American Medical Association 2001; 285:777-784.
46. Podzamczer D, Ferrer E, Consiglio E, Gatell J, Perez P, Perez J, Luna E, González A, Pedrol E & Lozano L. Final 12-month results from the COMBINE study: A randomized, open, multicenter trial comparing Combivir plus nelfinavir or nevirapine in naive patients. In Abstracts of the 1st International AIDS Society Conference on Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July, 2001, Abstract #7.
47. Ruane P, Mendonca J, Timerman A, Cernohous P, Bauer E, Bernstein B & Sun E. Kaletra vs. Nelfinavir in antiretroviral-naive subjects: Week 60 comparison in a Phase III, blinded, randomized clinical trial. In Abstracts of the 1st International AIDS Society Conference on Pathogenesis and Treatment, Buenos Aires, Argentina, 8-11 July, 2001, Abstract #6.
48. Vibhagool A, Cahn P, Schechter M, Soto-Ramirez L, Montroni M, Smaill F & Thomas N. Abacavir/Combivir™ (ABC/COM) is comparable to Indinavir/Combivir™ (IDV/COM) in HIV-1 infected antiretroviral therapy naïve adults: preliminary results of a 48 week open-label study (CNA3014). In Abstracts of the 1st International AIDS Society Conference on Pathogenesis and Treatment, Buenos Aires, Argentina, 8-11 July, 2001, Abstract #63.
49. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M & Katzenstein DA. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. New England Journal of Medicine 2001; 345:398-407.
50. Gulick R, Mellors J, Havlir D, Eron J, Gonzales C, Meibohm A, McMahon D, Robertson M & Richman D. Indinavir (IDV), zidovudine (ZDV), and lamivudine (3TC): 5-year follow-up. In Abstracts of the 1st International AIDS Society Conference on Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July, 2001, Abstract #215.
51. Cahn P, Casiró A, Puentes T, David D, Richter C, Stek M & Gatell J. Continued indinavir (80 mg TID) versus switching to indinavir+ritonavir (800/100 mg BID) in HIV patients having achieved viral load suppression. A randomized study: the BID efficacy and safety trial (BEST). In Abstracts of the 1st International AIDS Society Conference on Pathogenesis and Treatment, Buenos Aires, Argentina, 8-11 July, 2001, Abstract #60.